Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Presented through a collaboration between United States and Canadian Academy of Pathology and Physicians’ Education Resource®, LLC.
Acknowledgment of Support
This activity is supported by an educational grant from AbbVie.
How We Do It®: Pathology Considerations for Diagnosis and Therapeutic Decision Making in Hematologic Malignancies
Release Date: July 30, 2021
Expiration Date: July 30, 2022
Activity Overview
Clinical Cases and ConversationsTM, one of PER®’s signature educational formats, is a video-based program in which a panel of distinguished experts use clinical cases to provide clinical practice perspectives and engage in discussions on a particular clinical topic. In this activity, 4 key thought leaders will first provide an overview of the current best practice and emerging strategies for diagnostic and prognostic testing in hematologic malignancies. Then, each of the expert faculty will present cases and supporting data that illustrate the incorporation of molecular testing in the diagnosis and treatment planning in acute myeloid leukemia, chronic lymphocytic leukemia, and multiple myeloma.
Acknowledgement of Commercial Support
This activity is supported by an educational grant from AbbVie.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This educational program is directed toward pathologists and medical oncologists who diagnose or treat patients with hematologic malignancies. Nurses, nurse practitioners, physician assistants, and other health care professionals involved in the treatment and management of hematologic malignancies will also be invited to participate in the activity.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Outline guideline-based recommendations for molecular testing in hematologic malignancies
- Identify current and emerging biomarkers that can facilitate treatment planning in hematologic malignancies
- Evaluate clinical trial evidence in the context of how hematologic testing strategies can be utilized to optimize treatment outcomes in the setting of hematologic malignancies
- Integrate testing approaches to stratify risk, individualize treatment, and monitor treatment response in patients with hematologic malignancies
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
Faculty
Chief, Hematopathology Service
Department of Pathology and Laboratory Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Consultant: AbbVie, Loxo Oncology, Oren Bio, Roche, Seagen, Takeda Pharmaceutical Co
Associate Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Research Funding: AbbVie, Amgen, Astellas Pharma, Bristol Myers Squibb, Cardiff Oncology, Covance, Daiichi-Sankyo, Fate Therapeutics, Forty Seven, Genentech, Gilead, GlycoMimetics, Hanmi, Immunogen, Incyte, Karyopharm, Newave Pharmaceutical, Nohla Therapeutics, Novartis, Novimmune, Pfizer, Servier, Sobi, Sunesis Pharmaceuticals; Advisory/Consulting: AbbVie, Agios Pharmaceuticals, Amgen, Astellas Pharma, Bristol Myers Squibb, Celgene, Daiichi-Sankyo, Genentech, Gilead, Immunogen, Incyte, Jazz, Karyopharm, Novartis, Otsuka Pharmaceutical Co, Pfizer, Servier, Sunesis Pharmaceuticals, Syndax Pharmaceuticals, Trillium; Honoraria: AbbVie, Astellas Pharma, Bristol Myers Squibb, Immunogen, Incyte, Jazz, Novartis, Otsuka Pharmaceutical Co, Pfizer
Professor of Medicine, Harvard Medical School
Director of the Center for Prevention of Progression
Director of the Clinical Investigator Research Program
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Consultant/Advisor: AbbVie, Adaptive Biotech, Aptitude Health, Binding Site, Bristol Myers Squibb, Cellectar Biosciences, Curio Science, Genentech, GNS Healthcare, GlaxoSmithKline, Janssen, Karyopharm, Oncopeptides, Medscape, Sanofi, Takeda Pharmaceutical Co
Associate Director, Chao Family Comprehensive Cancer Center
Medical Director, Sue and Ralph Stern Center for Clinical Trials and Research
Professor, School of Medicine
University of California Irvine
Irvine, CA
Disclosures: Consultant/Research Support: AbbVie, Acerta Pharma, Alexion Pharmaceuticals, Amgen, Aptose Biosciences Inc, Astellas, Autolus Therapeutics, Bristol Myers Squibb, Caribou Biosciences, Celgene, Gilead, GlaxoSmithKline, Janssen, Johnson and Johnson, Juno Therapeutics, Kite Pharma, Merck, Nova Research Company, Pfizer, Pharmacyclics, Regeneron, Sunesis Pharmaceuticals, TG Therapeutics, Vaniam Group LLC, Verastem Oncology, Vida Ventures
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
